Skip to main content
. Author manuscript; available in PMC: 2022 May 2.
Published in final edited form as: Clin Sci (Lond). 2021 Jul 16;135(13):1545–1556. doi: 10.1042/CS20201367

Figure 3. Novel Therapeutics Shift Populations of PP2A Holoenzymes.

Figure 3.

(A) Schematic representation of how SMAPs and iHAPs act to stabilize a particular PP2A holoenzyme in disease settings where PP2A is inactivated. (B) Illustration of biased subunit assembly. DT-061 acts to shift the overall population of PP2A by selectively stabilizing the B56α containing holoenzyme with methylated C subunit.